Zacks Small Cap Research – ABEO: BLA Resubmission in 2H24 – Dream-Forge

By David Bautz, PhD NASDAQ: ABEO READ THE FULL ABEO RESEARCH REPORT Business Update BLA for Pz-cel to be Resubmitted in 2H24 Abeona Therapeutics, Inc. (NASDAQ:ABEO) is currently working on the resubmission of the Biologics License Application (BLA) for pz-cel (prademagene zamikeracel) for the treatment of recessive dystrophic epidermolysis bullosa (RDEB). In April 2024, the … Read more